To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study is a multi-site, unmasked phase IV study. Travacom(R) is a combination topical
ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by
complementary mechanisms of action. The safety and efficacy of both travoprost and timolol
have been established as single and adjunctive therapy in well-controlled clinical studies in
thousands of patients diagnosed with open angle glaucoma (OAG) or ocular hypertension. The
objective of this study is to assess the safety and efficacy of changing to Travacom from
prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular
hypertension across India.